Abstract:Background: Enantiodiscrimination of chiral drugs is critical for understanding physiological phenomena and ensuring medical safety. Although enantiomers of these drugs share identical physicochemical properties, they exhibit significant differences in pharmacodynamic, pharmacokinetic, and toxicological properties due to the differences in their three-dimensional shapes. Therefore, the development of effective methods for chiral recognition is of great significance and has been a hot topic in chemo/biological studies. Results: In this study, we designed a recognition receptor comprising a α-hemolysin (α-HL) nanopore and sulfobutyl ether-β-cyclodextrin (SBEβCD) for identifying the enantiomers of the antidepressant duloxetine at the single-molecule level. Chiral molecules were discriminated based on the different current blockages within the recognition receptor. The results indicated a strong interaction between R-duloxetine and the recognition receptor. By combining the experimental data and molecular docking results, we explored the recognition mechanism of the designed nanopore recognition receptor for chiral drug molecules. It was found that hydrophobic and electrostatic interactions play key roles in chiral recognition. Additionally, by comparing the binding kinetics of enantiomers to cyclodextrins in confined nanospace and bulk solution, we found that enantiomeric identification was better facilitated in the confined nanospace. Finally, the enantiomeric excess (ee) of the enantiomeric duloxetine mixture was measured using this recognized receptor. Significance: This strategy has the advantages of low cost, high sensitivity, and no need for additional derivative modifications, providing a new perspective on the development of chiral recognition sensors with excellent enantioselectivity in drug design, pharmaceuticals, and biological applications.

Understanding The Chiral Recognitions Between Neuraminidases And Inhibitors: Studies With Dft, Docking, And Md Methods

Insight into the Predictive Binding Modes of the Influenza a Neuraminidase in Complexes with Avian and Human Receptor Analogues

Discovery of Neuraminidase Inhibitors based on 3D-QSAR, Molecular Docking and MD Simulations

Binding Site Analysis, 3D-QSAR Studies, and Molecular Design of Flavonoids Derivatives As Potent Neuraminidase Inhibitors

Novel Binding Patterns Between Ganoderic Acids and Neuraminidase: Insights from Docking, Molecular Dynamics and Mm/Pbsa Studies

The Mechanism by Which 146-N-glycan Affects the Active Site of Neuraminidase

Bionic nanopore recognition receptors for single-molecule enantioselectivity studies of chiral drugs

Molecular Docking, 3d-Qsar Studies, And In Silico Adme Prediction Of P-Aminosalicylic Acid Derivatives As Neuraminidase Inhibitors

Selective Binding Of Antiinfluenza Drugs And Their Analogues To 'Open' And 'Closed' Conformations Of H5n1 Neuraminidase

QSAR Modeling and Molecular Interaction Analysis of Natural Compounds As Potent Neuraminidase Inhibitors

Balancing Interactions in Proline-Based Receptors for Chiral Recognition of L-/D-dopa

Docking and 3D-QSAR Investigations of Pyrrolidine Derivatives As Potent Neuraminidase Inhibitors.

Experimentally Probing the Chiral Recognition Mechanism of 1,1′-Bi-2-naphthol on a Nitrogen Enriched Chiral Metal-Organic Framework

The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations

Studies on synthesis and structure-activity relationship (SAR) of derivatives of a new natural product from marine fungi as inhibitors of influenza virus neuraminidase.

Binding mode of neuraminidase target of H1N1 influenza virus with three inhibitors

Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design

Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico.

Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.

Design,Synthesis and Anti-influenza Activities of Novel Neuraminidase Inhibitors

MedChemExpress compounds prevent neuraminidase N1 via physics- and knowledge-based methods